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Background: Ulmus davidiana var. japonica Rehder (UD) has long been used in traditional folk
medicine in Asia. This study is designed to investigate the antiadhesive activity of the
ethanol extract of UD (UDE) and its underlying mechanisms in cultured endothelial cells.
Methods: The dried root bark of UD was extracted with 80% (v/v) ethanol. The antiadhe-
sive activity of the UDE was investigated in cultured human umbilical vein endothelial
cells and human embryonic kidney epithelial 293T (HEK 293T) cells stably transfected with
pGL3-vascular cell adhesion molecule (VCAM)-1-luc. Monocyte adhesion in endothelial cells
was induced by tumor necrosis factor-alpha (TNF-), and the protective effects of UDE on
monocyte–endothelial cell adhesion, VCAM-1 expression, reactive oxygen species produc-
tion,  and nuclear factor-B  activity were determined.
Results: Exposure to UDE at a concentration of 3–30 g/mL for 24 hours produced no
detectable cytotoxicity in human umbilical vein endothelial cells, but it signiﬁcantly
inhibited TNF--induced monocyte adhesion and VCAM-1 expression. TNF- treatment
of  HEK 293T/VCAM-1-luc cells resulted in increased luciferase activity of the VCAM-1 pro-
moter, which was inhibited by treatment with UDE. Additionally, TNF--induced reactive
oxygen species generation, nuclear translocation of nuclear factor-B, and IB degrada-
tion in human umbilical vein endothelial cells were effectively reduced by treatment with
30  g/mL of UDE.
Conclusion: Our results indicated that UDE treatment inhibited TNF--induced monocyteadhesion in endothelial c
mation.
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1.  Introduction
The vascular endothelium plays a central role in the regulation
of vascular homeostasis. Alterations in endothelial function
have been linked to a variety of inﬂammatory diseases, includ-
ing atherosclerosis and diabetes mellitus.1 Proinﬂammatory
cytokines, such as tumor necrosis factor-alpha (TNF-),  induce
endothelial dysfunction by causing an increase in the expres-
sion of cell-surface adhesion molecules, such as vascular
cell adhesion molecule (VCAM)-1. These changes facilitate
the adhesion of circulating blood cells, including neutrophils,
leukocytes, and monocytes, to activated endothelial cells, ulti-
mately leading to endothelial dysfunction.2
Monocyte rolling and adhesion to vascular endothelial cells
are initial steps in the development of vascular inﬂammation.3
Among the adhesion molecules, VCAM-1 is a key molecule in
the recruitment of leukocytes to endothelial cells. Upregulated
VCAM-1 expression in endothelial cells is associated with
several cardiovascular diseases that involve vascular inﬂam-
mation. Nuclear factor (NF)-B signaling also plays a pivotal
role in vascular inﬂammation.4
Ulmus davidiana var. japonica Rehder (Urticales: Ulmaceae)
(UD) has traditionally been used for anticancer and anti-
inﬂammatory therapy in Asia.5,6 Several compounds have
been extracted from the stem and root barks of UD,
and their functions have been investigated.7–9 In previous
reports, an extract of UD (UDE) was found to attenu-
ate ovalbumin-induced airway inﬂammation by increasing
hemooxygenase-1 expression, and methanol extracts of
UD showed an antiangiogenic effect.10,11 Recently, UDE
was reported to induce vasorelaxation in an endothelium-
dependent manner in rat aorta, suggesting that the vascular
endothelium is the target tissue of UDE and that it has a pro-
tective effect against endothelial dysfunction.12 However, the
effect of UDE on monocyte adhesion to the endothelial cells
remains unclear. This study aimed to examine the protective
effect of UDE on TNF--induced monocyte adhesion and elu-
cidate its underlying mechanism.
2.  Materials  and  methods
2.1.  Materials
The human monocyte cell line U937 and the human embry-
onic kidney cell line [human embryonic kidney epithelial 293T
(HEK 293T)] were obtained from the American Type Culture
Collection (Rockville, MD, USA), and human umbilical vein
endothelial cells (HUVECs) were obtained from Lonza (Walk-
ersville, MD, USA). Dulbecco’s modiﬁed Eagle’s medium, fetal
bovine serum, and antibiotics were purchased from Gibco
(Grand Island, NY, USA), and an endothelial growth medium
(EGM-2) SingleQuot kit was purchased from Lonza. Human
TNF- was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Dichloroﬂuorescein diacetate (H2DCFDA) and 2′,7′-bis-(2-
carboxyethyl)-5-(and-6)-carboxy-ﬂuorescein acetoxymethyl
ester probes were purchased from Molecular Probes (Eugene,
OR, USA). Antibodies against VCAM-1, NF-B p65, IB,
poly (ADP-ribose) polymerase (PARP), and glyceraldehydeIntegr Med Res ( 2 0 1 6 ) 131–139
3-phosphate dehydrogenase (GAPDH) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA), and -actin
antibody was purchased from Sigma-Aldrich.
2.2.  Cell  cultures  and  treatment  with  UD  ethanol
extracts
HUVECs were cultured in an endothelial growth medium
(EGM-2), and the cells were used for up to six passages, accord-
ing to the manufacturer’s instructions. U937 and HEK 293T cell
lines were maintained in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% (v/v) fetal bovine serum and antibi-
otics at the manufacturer’s recommended concentration. Each
cell line was incubated in an atmosphere of 95% air and 5%
CO2 at 37 ◦C. Ethanol extract of UD was prepared as described
previously.12 The freeze-dried UDE was thoroughly dissolved
in dimethyl sulfoxide (DMSO) at a concentration of 1 mg/mL
prior to use in experiments. HUVECs at 80–90% conﬂuence
were treated with various concentrations of UDE  (1–30 g/mL).
As a vehicle-negative control, HUVECs were incubated in a cul-
ture medium containing DMSO (0.1%, v/v). Then HUVECs were
stimulated with 15 ng/mL of TNF-.
2.3.  Cell  viability  measurement  using  bioluminescent
assay
The effect of UDE on the viability of HUVECs was analyzed
using a RealTime-Glo MT luminescent kit (Promega, Madi-
son, WI,  USA) in an opaque-walled assay plate, according
to the manufacturer’s instructions. The permeable viability
prosubstrate in live cells is reduced to a luciferase sub-
strate by metabolically active cells, while dead cells neither
reduce the substrate nor produce a signal. The reduced
substrate diffuses from cells into the surrounding culture
medium and is then rapidly used by luciferase to produce
a luminescent signal, which shows a correlation with via-
bility. HUVECs in the assay-plate were treated with various
concentrations of UDE (1–30 g/mL) for 24 hours. To contin-
uously monitor the viability of the treated HUVECs in real
time, the prosubstrate and luciferase were added at the same
time as the UDE. Luminescence intensity at the desired time
points was measured using a luminometer (Thermo Scien-
tiﬁc, Rockford, IL, USA). Each sample was analyzed at least in
triplicate.
2.4.  Measurement  of  reactive  oxygen  species
The intracellular reactive oxygen species (ROS) level was
measured using a membrane-permeant H2DCFDA ﬂuorogenic
probe, as described previously.13 Brieﬂy, 1 × 105 cells were
seeded in a 12-well plate and allowed to attach overnight.
The cells were pretreated with various concentrations of UDE
(1–30 g/mL) for 1 hour and then stimulated with 15 ng/mL of
TNF- for 3 hours. Subsequently, the cells were stained with
◦5 M H2DCFDA for 30 minutes at 37 C. The cells were col-
lected, and ﬂuorescence was measured using a Fluoroskan
Ascent microplate reader (Thermo Scientiﬁc) at wavelengths
of 485 nm for excitation and 530 nm for emission.
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(1–30 g/mL), but decreased viability was detected at 50 g/mL
of UDE (Fig. 1). HUVECs demonstrated more  than 95% viability
at 30 g/mL UDE, indicating that it did not cause nonspeciﬁc
Fig. 1 – UDE treatment did not cause any detectable
reduction of cell viability at 3–30 g/mL in HUVECs. The
effect of UDE treatment for 24 hours on HUVEC viability at
the indicated concentrations (0–50 g/mL) was determined
by a bioluminescent assay and then compared with that of
DMSO-treated control cells. Data are presented as means ±
SEM (n = 3). Similar results were  observed in replicate
experiments.
* p < 0.05, compared with DMSO-treated control cells, as.M. Lee et al/Ulmus davidiana ethanol extract inhibits monocyte adhesi
.5.  Monocyte–endothelial  cell  adhesion  assay
he monocyte–endothelial cell adhesion assay was per-
ormed as previously described.14 Brieﬂy, U937 monocytes
1 × 107 cells/mL) were incubated with 1 M 2′,7′-bis-(2-
arboxyethyl)-5-(and-6)-carboxy-ﬂuorescein acetoxymethyl
ster for 30 minutes at 37 ◦C in Dulbecco’s modiﬁed Eagle’s
edium. HUVECs (3 × 104 cells/well) were seeded in 96-well
lates and grown until they reached conﬂuent monolayers,
nd then pretreated with various concentrations of UDE
1–30 g/mL) for 1 hour, followed by stimulation with 15
g/mL of TNF- for 18 hours. The ﬂuorescent-labeled U937
onocytes were then added to the TNF--stimulated HUVECs
nd incubated for further 2 hours. After washing out the
nbound U937 three times, the amount of adherent mono-
ytes was analyzed by measuring the ﬂuorescent intensity at
avelengths of 485 nm for excitation and 530 nm for emission.
ells containing HUVECs alone were used as blanks.
.6.  Immunoblotting
ells were harvested and the cell lysates were prepared as
reviously described.15 The total protein concentration was
easured using the Bradford assay. For some experiments,
uclear and cytosolic fractions were prepared using a cell
ractionation kit (Abcam, Cambridge, UK).13 The purity of the
uclear fraction was conﬁrmed using an antibody against the
uclear marker PARP. The same concentration of protein was
esolved by sodium dodecyl sulfate - polyacrylamide gel elec-
rophoresis (SDS-PAGE) and transferred onto a polyvinylidene
uoride membrane. Immunoblotting was performed using
nti-VCAM-1, NF-B p65, IB, PARP, GAPDH, and -actin anti-
odies. The intensity of bands was quantiﬁed in an EpiChem
 Darkroom using LabWorks software (UVP, Upland, CA, USA),
ollowed by normalization of band densities to -actin.
.7.  Immunocytochemistry
mmunocytochemical localization of the NF-B p65 subunit
as performed as previously described.16 HUVECs were cul-
ured on glass coverslips in 12-well plates and treated with
NF- after pretreatment with 10 g/mL UDE. After washing
ith phosphate-buffered saline (PBS), cells were ﬁxed with
% (w/v) paraformaldehyde and permeabilized with 0.1% (v/v)
riton X-100. After blocking for 1 hour with PBS containing
% (w/v) bovine serum albumin and 5% (v/v) horse serum,
ells were incubated with NF-B p65 antibody (1:500) overnight
t 4 ◦C and then labeled with Alexa Fluor 488-conjugated
econdary antibody (1:500) for 1 hour in the dark at room tem-
erature. Images were obtained by ﬂuorescence microscopy.
.8.  Luciferase  assay  using  in  vitro  imaging
or this experiment, HEK 293T cells were cotransfected with
GL3.1 VCAM-1 promoter ﬁreﬂy luciferase reporter plasmid
nd pcDNA4, and selected by 0.4 mg/mL  Zeocin in culture for weeks. To establish a clonal population stably expressing a
omogenous level of luciferase, a couple of different clones
ere isolated to represent different intensities of luciferase
ctivity. Following expansion, each clone was analyzed using133
a Lumina XRMS in vitro imaging system (PerkinElmer Inc.,
Waltham, MA, USA) to ensure luciferase activity. The HEK
293T/VCAM-1-luc cells were plated in an opaque-walled 96-
well plate (4 × 104 cells/well) and allowed to attach overnight.
The cells were incubated with UDE in a concentration-
dependent manner for 1 hour, followed by TNF- stimulation
and then further incubation for 6 hours. Subsequently, the
cells were treated with luciferin for 30 minutes at 37 ◦C, and
the resulting biophotonic reaction was measured using the
Lumina XRMS imaging system and analyzed using Living
Image Software 4.4 (PerkinElmer Inc.).
2.9.  Statistical  analysis
The data are expressed as the mean ± standard error of the
mean (SEM). Statistical signiﬁcance was analyzed by one-way
analysis of variance (ANOVA) followed by Dunnett’s or Bon-
ferroni’s multiple comparison tests using Prism 5 software
(GraphPad, La Jolla, CA, USA), and p < 0.05 was considered sig-
niﬁcant.
3.  Results
3.1.  Effect  of  UDE  on  the  viability  of  HUVECs
To investigate the potential cytotoxic effects of UDE, the effect
of UDE treatment on the viability of HUVECs was examined
using a bioluminescent assay. HUVEC viability was consis-
tently high at the desired treatment concentrations of UDEcalculated by one-way ANOVA followed by Dunnett’s test.
ANOVA, analysis of variance; DMSO, dimethyl sulfoxide;
HUVEC, human umbilical vein endothelial cell; SEM,
standard error of the mean; UDE, U. davidiana extract.
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cytotoxicity at the highest concentration used for treatments
(Fig. 1). The treated HUVECs were also observed under phase-
contrast microscopy, and no effects on HUVEC morphology
could be observed after UDE treatment even at 30 g/mL
(data not shown). Collectively, it was determined that UDE
treatment did not affect HUVEC viability adversely, and con-
centrations of < 30 g/mL can be considered safe.
3.2.  Effect  of  UDE  on  monocyte  adhesion  in
TNF-˛-stimulated  HUVECs
Recently, much evidence for the anti-inﬂammatory biological
activity of natural agents has been reported in vascular
inﬂammation models. The anti-inﬂammatory activity of
these agents has generally been reported to be mediated
by the inhibition of ROS generation, expression of adhesion
molecules, and NF-B activity, leading to reduced leukocyte
adherence in the process of leukocyte trafﬁcking. We  deter-
mined the effect of UDE treatment on monocyte adhesion
to endothelial cells. HUVECs were pretreated with the UDE
(3–30 g/mL) and then incubated with TNF- for 18 hours.
Adhesion of ﬂuorescently labeled monocytes to stimulated
Fig. 2 – Quantitative adhesion assay of U937 monocytes to TNF-
concentrations of UDE (0–30 g/mL) for 1 hour followed by treatm
monocytes were  added onto TNF--stimulated HUVECs and then
cells adhering to the HUVECs were  observed under a ﬂuorescent
cells adhering to HUVECs was determined using a ﬂuorometer. D
with similar results. Results are presented as means ± SEM (n = 3
* p < 0.001, compared with untreated control cells, as calculated b
comparison tests.
† p < 0.01, compared with control cells treated with TNF--only, a
multiple comparison tests.
ANOVA, analysis of variance; HUVEC, human umbilical vein end
tumor necrosis factor-alpha; UDE, U. davidiana extract.Integr Med Res ( 2 0 1 6 ) 131–139
endothelial cells was observed under ﬂuorescent microscopy
(Fig. 2A). TNF--induced monocyte adhesion was inhibited by
UDE treatment in a concentration-dependent manner. Expo-
sure to 30 g/mL UDE resulted in a 21% decrease in monocyte
adhesion compared with that in the DMSO-treated control
cells (Fig. 2B). The decrease in ﬂuorescence intensity induced
by UDE treatment was found to occur in a concentration-
dependent manner. These results indicated that UDE may
inhibit monocyte adherence to the endothelial cell surface.
3.3.  Effects  of  UDE  on  the  adhesion  molecule  VCAM-1
During the process of monocyte trafﬁcking, monocyte
adherence is largely controlled by the regulation of surface-
expressed, cell adhesion molecules in response to secreted
chemokines. To examine whether UDE treatment modiﬁed
monocyte adhesion by causing an altered expression of cell-
surface adhesion molecules, we determined the expression
level of the adhesion molecule VCAM-1 on the surface of TNF-
-stimulated HUVECs. Exposure of HUVECs to TNF- induced
a signiﬁcant upregulation of VCAM-1 expression (Fig. 3A,
3B). Treatment with UDE caused a signiﬁcant inhibition
-stimulated HUVECs. HUVECs were pretreated with various
ent with TNF- for 18 hours. Fluorescent-labeled U937
 incubated for 90 minutes. (A) Fluorescent-labeled U937
 microscopy at 100× magniﬁcation. (B) The number of U937
ata are representative of three independent experiments
).
y one-way ANOVA followed by Bonferroni’s multiple
s calculated by one-way ANOVA followed by Bonferroni’s
othelial cell; SEM, standard error of the mean; TNF-,
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Fig. 3 – UDE treatment resulted in altered expression levels of the adhesion molecule VCAM-1 in TNF--stimulated HUVECs.
(A) Immunoblotting for adhesion molecule VCAM-1 using lysates from TNF--stimulated HUVECs treated with DMSO or
UDE at the indicated concentrations (0–30 g/mL). Blots were  stripped and reprobed with anti--actin antibody to correct for
differences in protein loading. (B) The expression of VCAM-1 relative to that of -actin was calculated for each treatment
group based on the densitometric scanning data of each band. Similar results were  observed in replicate experiments
(n = 3). (C and D) The transcriptional activity of VCAM-1 in TNF--stimulated HEK 293T cells was determined by a luciferase
reporter gene assay. HEK 293T/VCAM-1-luc cells (4 × 104 cells/well) were  plated in a black 96-well plate following treatment
with various concentrations (0–30 g/mL) of UDE and then stimulated with TNF- for 6 hours. (C) The bioluminescent
images were  taken following the addition of D-luciferin substrate (150 g/mL ﬁnal concentration). (D) The luciferase activity,
in units of total ﬂux (photons/s) was quantiﬁed using an IVIS Lumina XRMS imaging system and analyzed by Living Image
Software 4.4 (PerkinElmer Inc.). Values are expressed as the mean ± SEM (n = 3).
* p < 0.001, compared with untreated control cells, as calculated by ANOVA followed by Bonferroni’s multiple comparison
tests.
† p < 0.01 compared with control cells treated with TNF--only, as calculated by ANOVA followed by Bonferroni’s multiple
comparison tests.
ANOVA, analysis of variance; DMSO, dimethyl sulfoxide; HEK, human epithelial kidney; HUVEC, human umbilical vein
endothelial cell; SEM, standard error of the mean; TNF-, tumor necrosis factor-alpha; UDE, U. davidiana extract; VCAM,
v
o
d
c
i
V
1
V
a
V
1
R
V
t
c
i
Sascular cell adhesion molecule.
f TNF--induced VCAM-1 expression in a concentration-
ependent manner. At the maximum tested treatment
oncentration of UDE (30 g/mL), the TNF--induced increase
n VCAM-1 expression was decreased by 36% (Fig. 3A, 3B).
Additionally, we analyzed the transcriptional activity of
CAM-1 using a luciferase reporter assay in HEK 293T/VCAM-
-luc cells, which were stably transfected with the human
CAM-1 promoter gene, and the results are shown in Fig. 3C
nd 3D. Indeed, an increase in the transcriptional activity of
CAM-1 was observed in TNF--stimulated HEK293T/VCAM-
-luc cells, which exhibited a bright biophotonic emission.
epresentative image  and relative luciferase activities for
CAM-1 in TNF--stimulated HEK293T/VCAM-1-luc cells, after
reatment with UDE, are shown in Fig. 3C and 3D. A signiﬁ-
ant decrease in VCAM-1 transcriptional activity was observed
n UDE-treated TNF--stimulated HEK 293T/VCAM-1-luc cells.
imilar to the results for VCAM-1 expression (Fig. 3A), UDEtreatment was also found to elicit a downregulation of VCAM-
1 transcriptional activity. Owing to treatment with UDE  at
30 g/mL, TNF--induced VCAM-1 transcriptional activity was
inhibited by 17.4% (Fig. 3D).
3.4.  Effect  of  UDE  on  ROS  generation  in
TNF-˛-stimulated  HUVECs
Next, intracellular ROS generation in TNF--stimulated
HUVECs after UDE treatment was measured using the
H2DCFDA ﬂuorescent probe. As shown in Fig. 4, TNF- stimula-
tion induced increased intracellular ROS generation compared
with that measured in DMSO-treated control cells. How-
ever, treatment with UDE led to a downregulation of ROS
generation in a concentration-dependent manner, compared
with that in HUVECs treated with TNF- alone. In particular,
treatment with 30 g/mL UDE almost completely abrogated
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Fig. 4 – Treatment of UDE inhibited ROS generation in
TNF- stimulated HUVECs. HUVECs were  pretreated with
various concentrations (3–30 g/mL) of UDE for 1 hour,
followed by treatment with TNF- for 3 hours. Then cells
were labeled with the H2O2-sensitive ﬂuorescent probe,
5 mM  of H2DCFDA at 37 ◦C for 30 minutes. The ﬂuorescence
intensity in the cells was immediately assayed using a
ﬂuorometer. Data are presented as means ± SEM (n = 3).
* p < 0.01 compared with untreated control cells, as
calculated by ANOVA followed by Bonferroni’s multiple
comparison tests.
† p < 0.05 compared with control cells treated with
TNF--only, as calculated by ANOVA followed by
Bonferroni’s multiple comparison tests.
ANOVA, analysis of variance; H2DCFDA, dichloroﬂuorescein
diacetate; HUVEC, human umbilical vein endothelial cell;
ROS, reactive oxygen species; SEM, standard error of the
mean; TNF-, tumor necrosis factor-alpha; UDE, U.
davidiana extract.
TNF--induced ROS generation, suggesting that UDE could
effectively attenuate endothelial dysfunction by inhibiting
TNF--induced ROS generation.
3.5.  Effect  of  UDE  on  NF-B  localization  and  signaling
in TNF-˛-treated  HUVECs
The transcription factor NF-B, which acts as a central medi-
ator of inﬂammatory responses, has been known to regulate
the expression of adhesion proteins in TNF--induced vascu-
lar inﬂammation.17,18 The anti-inﬂammatory effect of many
natural products results from the inhibition of NF-B activ-
ity in various cell types, which explains our results on
UDE-mediated downregulation of the VCAM-1 proteins in
TNF--stimulated HUVECs (Fig. 3A). To conﬁrm the inhibition
of NF-B in TNF--stimulated HUVECs under our experimen-
tal conditions, we  determined the effect of UDE treatment
on nuclear translocation of NF-B p65, which is necessary
for its activation. Initially, we  performed immunoblotting for
NF-B p65 using nuclear and cytosol fractions prepared from
TNF--stimulated HUVECs treated with different concentra-
tions of UDE for 1 hour. As shown in Fig. 5A, UDE treatment
caused a marked decrease in the nuclear level of NF-B p65
that was evident as low as 3 g/mL UDE after treatment. The
UDE-mediated inhibition was also evident from a recipro-
cal increase of cytoplasmic localization of NF-B p65 at theIntegr Med Res ( 2 0 1 6 ) 131–139
same concentration (Fig. 5A). The membranes were stripped
and reprobed with anti-PARP and/or GAPDH antibodies to
ensure equal protein loading, as well as to rule out cross-
contamination of nuclear and cytoplasmic fractions (Fig. 5A).
Additionally, IB degradation, which is a critical step for NF-
B activation leading to nuclear translocation, was obviously
prevented even with 3 g/mL UDE treatment (Fig. 5B).
Next, we performed immunocytochemistry to further
examine the effect of UDE treatment on nuclear/cytoplasmic
localization of NF-B p65. As shown in Fig. 5C, the NF-B p65
(green ﬂuorescence) immunostaining was evident in both the
nucleus (red ﬂuorescence) and the cytoplasm of nonstimu-
lated HUVECs compared with the mainly nuclear localization
of NF-B p65 in TNF--stimulated cells. Similar to the result
of Fig. 5A, UDE treatment signiﬁcantly attenuated TNF--
induced nuclear translocation of NF-B p65 and restricted it
to the cytoplasm, indicating inhibition of its nuclear translo-
cation and its activity (Fig. 5C).
4.  Discussion
Here, we demonstrated that UDE treatment inhibits TNF--
induced monocyte adhesion to endothelial cells, and that its
antiadhesive activity might be due to the inhibition of VCAM-1
protein and/or transcriptional activity for VCAM-1.
In the present study, we showed the effect of UDE on
endothelial cell viability. UDE at a concentration of less
than 30 g/mL exerted antiadhesive activity without affecting
endothelial cell viability. However, a high dose of UDE (more
than 50 g/mL) reduced cell viability, suggesting nonspeciﬁc
cell toxicity at such high doses. UD is also used as a traditional
medicine for its antitumor activities. In previous reports, UDE
(more than 50 g/mL) exerted antitumor activity.19 Therefore,
pharmacological use of high doses of UDE may be possible,
but requires further study and careful consideration of the
beneﬁts and risks. Our cell viability results could serve as fun-
damental data for the development of antitumor drugs lacking
nonspeciﬁc cell toxicity.
Adhesion of circulating monocytes to the arterial endothe-
lium is the initial event in the development of chronic
inﬂammatory diseases such as atherosclerosis, and it is
mainly regulated by a combination of cell-surface adhesion
molecules. VCAM-1 is an adhesion protein that appears on
the surface of endothelial cells after exposure to inﬂamma-
tory cytokines. VCAM-1 is a ligand for the integrin receptor
very late activation antigen (VLA)-4.20 Binding of VCAM-1 to
VLA-4 is a key regulator of monocyte adhesion in endothe-
lial cells. The area of early atherosclerotic lesions in the aorta
was reduced signiﬁcantly in VCAM-1 knockout mice, indicat-
ing that VCAM-1 plays a dominant role in the initiation of
atherosclerosis.21
In the present study, UDE treatment inhibited TNF--
induced monocyte adhesion in endothelial cells. Additionally,
western blot and promoter assays revealed that the anti-
adhesive activity of UDE is mainly due to the inhibition
of TNF--induced VCAM-1 protein expression and its trans-
criptional activity. Especially, the effect of UDE  on the
transcriptional activity of VCAM-1 was evaluated in stable cell
lines to avoid variable protein expressions among individual
K.M. Lee et al/Ulmus davidiana ethanol extract inhibits monocyte adhesion 137
Fig. 5 – Treatment of HUVECs with UDE signiﬁcantly inhibited TNF--induced NF-B activity. (A) A representative NF-B
immunoblot using fractionated nuclear and cytosolic cell lysates from HUVECs stimulated with TNF- following treatment
with various concentrations (0–30 g/mL) of UDE for 1 hour. PARP and GAPDH were  used as loading controls for nuclear and
cytosolic proteins, respectively. (B) Immunoblot for IB. HUVECs were pretreated with various concentrations (0–30 g/mL)
of UDE for 1 hour and then stimulated with TNF- for 30 minutes. The blot was stripped and reprobed with -actin antibody
to correct for differences in protein loading. Similar results were observed in replicate experiments (n = 3). (C)
Immunocytochemistry for the analysis of NF-B p65 localization following exposure to DMSO or 30 g/mL UDE  in
TNF--stimulated HUVECs for 30 minutes. Green and red ﬂuorescence indicate staining for NF-B p65 and for the cell
nucleus, respectively. Images were merged to detect the nuclear/cytosolic distribution of NF-B p65. Images are
representative of three different experiments.
DMSO, dimethyl sulfoxide; HUVEC, human umbilical vein endothelial cell; NF-B, nuclear factor-B; PARP, poly (ADP-ribose)
p idia
c
s
+
(
l
i
d
U
p
s
d
t
s
a
s
U
e
e
eolymerase; TNF-, tumor necrosis factor-alpha; UDE, U. dav
ells that can occur with transient transfection. We  generated
table HEK293T cell lines containing the region from –1716 to
119 of the human VCAM-1 promoter into pGL3.1 plasmids
kindly donated by Y.G. Kwon, Yonsei University).22 Then, this
uciferase activity was analyzed using a high-sensitivity in vitro
maging system to visualize the luciferase signal. A signiﬁcant
ecrease in VCAM-1 transcriptional activity was conﬁrmed in
DE-treated TNF--stimulated HEK 293T/VCAM-1-luc cells.
ROS are created by a variety of cellular processes as
art of cellular signaling events.23 Proinﬂammatory cytokines,
uch as TNF-, increase ROS generation in inﬂammatory
iseases.24,25 In particular, Nicotinamide adenine dinucleo-
ide phosphate (NADPH) oxidase and mitochondrial ROS were
hown to be involved in TNF--induced VCAM-1 expression
nd monocyte adhesion in endothelial cells.26 In the present
tudy, our data showed that treatment of cells with 30 g/mL
DE almost completely abrogated TNF--induced ROS gen-
ration, suggesting that UDE could effectively attenuate
ndothelial dysfunction by inhibiting TNF--induced ROS gen-
ration.na extract.
NF-B is regulated by the intracellular redox status.23 It
has been reported that oxidants that enhance ROS genera-
tion also induce NF-B activation. Indeed, excess generation
of ROS is involved in the majority of signaling pathways
that cause IB degradation and NF-B nuclear accumulation.
Transcriptional activation of NF-B increases the expression of
adhesion molecules, such as VCAM-1, subsequently leading to
monocyte adhesion and transmigration across the endothe-
lial barrier into the vessel wall.17,18 In this study, we  clearly
demonstrated that UDE attenuates TNF--induced NF-B p65
nuclear translocation and IB degradation. Therefore, given
these correlations between NF-B and endothelial dysfunc-
tion, we can speculate that UDE suppresses NF-B signaling.
Several kinds of candidate natural compounds can be
involved in antiadhesive activity. Phytochemical components
of UD that have been demonstrated to have cytoprotec-
tive effects in a puriﬁed form include epigallocatechin-
3-gallate, catechin, triterpene ester, and sesquiterpene
O-naphthoquinones.27–30 Based on our knowledge, UDE  has
been shown to have antiadhesive and vasorelaxant activities.
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Therefore, UDE could be used as a part of a drug formula to
inhibit chronic vascular inﬂammation, enhance blood ﬂow,
and/or facilitate blood circulation.
5.  Conclusion
Taken together, we  demonstrated that UDE inhibits TNF--
induced monocyte adhesion in endothelial cells and that its
antiadhesive activity was at least partly due to the inhibition
of VCAM-1 expression, which is regulated by ROS and NF-B
signaling. Our results provide new insight into the cellular
mechanisms underlying the protective activity of UDE against
endothelial dysfunction in chronic vascular inﬂammatory
diseases.
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